R Douglas Scott
Affiliation: Centers for Disease Control and Prevention
- Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysisR Douglas Scott
Division of Healthcare Quality Promotion Scott, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
Am J Prev Med 23:98-105. 2002..Surveillance of meningococcal disease among U.S. college students found an elevated rate of this disease among first-year students living in dormitories...
- Collecting data to assess SARS interventionsR Douglas Scott
National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
Emerg Infect Dis 10:1290-2. 2004..We propose a minimum dataset to capture data needed to examine the basic reproduction rate, case status and criteria, symptoms, and outcomes of SARS...
- West Nile virus economic impact, Louisiana, 2002Armineh Zohrabian
Division of Adult and Community Health, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA
Emerg Infect Dis 10:1736-44. 2004..4 million dollars medical and US 6.5 million dollars nonmedical costs) and a US 9.2 million dollars cost of public health response. These data indicate a substantial short-term cost of the WNV disease epidemic in Louisiana...
- Cost-effectiveness of conjugate meningococcal vaccination strategies in the United StatesColin W Shepard
Division of Viral Hepatitis, National Center for Infectious Diseases, US Centers for Disease Control and Prevention, 1600 Clifton Rd, MS G37, Atlanta, GA 30333, USA
Pediatrics 115:1220-32. 2005..The US Food and Drug Administration approved a meningococcal conjugate A/C/Y/W-135 vaccine (MCV-4) for use in persons aged 11 to 55 years in January, 2005; licensure for use in younger age groups is expected in 2 to 4 years...
- The economic burden of drug resistanceDavid H Howard
Department of Health Policy and Management, Emory University, Atlanta, GA 30322, USA
Clin Infect Dis 41:S283-6. 2005..Understanding to what degree prescribing patterns are driven by real versus perceived limitations of first-line drugs is important for assessing the ability of public health campaigns to change the behavior of patients and providers...
- Costs of management of occupational exposures to blood and body fluidsR Douglas Scott
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Infect Control Hosp Epidemiol 28:774-82. 2007..To determine the cost of management of occupational exposures to blood and body fluids...
- The global impact of drug resistanceDavid H Howard
Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
Clin Infect Dis 36:S4-10. 2003..In some instances, these costs may exceed those attributable to treatment failure...
- The cost of care for patients with HIV from the provider economic perspectiveRebecca R Roberts
Department of Emergency Medicine, John H Stroger, Jr Hospital of Cook County, 1900 W Polk Street, 10th Floor, Chicago, Illinois 60612, USA
AIDS Patient Care STDS 20:876-86. 2006..We postulate that reimbursement rates have not captured the recent flourishing of ambulatory care. If reimbursement is not commensurate with outpatient advances, providers may be paradoxically underreimbursed for improving care...
- The use of economic modeling to determine the hospital costs associated with nosocomial infectionsRebecca R Roberts
Department of Emergency Medicine, Cook County Hospital, Rush University, Chicago, IL, USA
Clin Infect Dis 36:1424-32. 2003..The economic model explained 56% of the total variability in cost among patients. Hospitals can use these data when evaluating potential cost savings from effective infection-control measures...